What are the differences in health technology assessment (HTA) across Europe?
Is denosumab superior to zoledronic acid in the treatment of bone metastases in MM?
Obinutuzumab and venetoclax for high-risk CLL: upcoming CLL14 trial
Highlights from EHA 2016 press briefings: Nivolumab, SGN-CD33A and hemophilia
Biosimilars: informing patients and physicians